Evidence map›Paper›PMID 33959997›Full record

ArticleMuscle & nerve2021

Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).

Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, Jeffrey T Guptill, Michael K Hehir, Katherine Ruzhansky, Leeann B Burton, David Post, Gary Cutter, Robin Conwit and 3 more

Abstract read
In one paragraph

Article in Muscle & nerve, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability.Annals of clinical and translational neurology · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amanda C GuidonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-0843-2935
Srikanth Muppidi *Department of Neurology, Stanford University Hospital, Palo Alto, California, USA.
Richard J Nowak *Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
Jeffrey T GuptillDepartment of Neurology, Duke University, Durham, North Carolina, USA.
Michael K HehirDepartment of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Katherine RuzhanskyDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Leeann B BurtonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
David PostDepartment of Neurology, Stanford University Hospital, Palo Alto, California, USA.
Gary CutterDepartment of Biostatistics, University of Alabama, Birmingham, Alabama, USA.
Robin ConwitDivision of Clinical Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, NINDS, Rockville, Maryland, USA.
Nicte I MejiaDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Henry J KaminskiDepartment of Neurology, George Washington University Medical Center, Washington, District of Columbia, USA.
James F HowardDepartment of Neurology, The University of North Carolina, Chapel Hill, North Carolina, USA.

Funding

Rare Disease Network for Myasthenia GravisU54NS115054 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI HENRY J KAMINSKI · 2019 to 2026
$11.9M
MGNet U54 NS115054, which is funded through collaboration between NCATS and NINDS.NINDS NIH HHS U54 NS115054
6 · The paper itself

Abstract

INTRODUCTION/

aimsTelemedicine may be particularly well-suited for myasthenia gravis (MG) due to the disorder's need for specialized care, its hallmark fluctuating muscle weakness, and the potential for increased risk of virus exposure among patients with MG during the coronavirus disease 2019 (COVID-19) pandemic during in-person clinical visits. A disease-specific telemedicine physical examination to reflect myasthenic weakness does not currently exist.

methodsThis paper outlines step-by-step guidance on the fundamentals of a telemedicine assessment for MG. The Myasthenia Gravis Core Exam (MG-CE) is introduced as a MG-specific, telemedicine, physical examination, which contains eight components (ptosis, diplopia, facial strength, bulbar strength, dysarthria, single breath count, arm strength, and sit to stand) and takes approximately 10 minutes to complete.

resultsPre-visit preparation, remote ascertainment of patient-reported outcome scales and visit documentation are also addressed. DISCUSSION: Additional knowledge gaps in telemedicine specific to MG care are identified for future investigation.

Indexed as

PhysiciansCOVID-19FemaleHumansMaleMyasthenia GravisPatient Education as TopicPhysical ExaminationTelemedicineCOVID-19myasthenia gravisoutcome measuresphyscial examinationtelemedicine

Identifiers

PMID33959997
PMCPMC9057373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.